| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expenses) | -25,966 | -10,584 | 2,362 | 839 |
| Loss before income taxes | - | - | - | -3,001 |
| Net loss | -29,752 | -30,364 | -4,143 | -3,001 |
| Net (income) loss attributable to noncontrolling interest | 29 | 100 | -4 | 33 |
| Net loss attributable to lineage | -29,781 | -30,464 | -4,139 | -3,034 |
| Basic net loss per share | -0.13 | -0.13 | -0.02 | -0.02 |
| Diluted net loss per share | -0.13 | -0.13 | -0.02 | -0.02 |
| Weighted average number of shares outstanding, basic, total | 228,853,000 | 228,356,000 | 226,054,000 | 188,835,000 |
| Weighted average number of shares outstanding, diluted | 228,853,000 | 228,356,000 | 226,054,000 | 188,835,000 |
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)